Showing 2714 results
-
Press Release /Entresto reversed trend of worsening New York Heart Association (NYHA) class - a key measure of the severity of a patient's heart failure symptoms - improving common…
-
Press Release /Subgroup of patients had a 25% reduction in major adverse cardiovascular events when treated with canakinumab in a new analysis of Phase III CANTOS trial presented at the American Heart Association…
-
Press Release /RTH258 demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity and meets primary endpoint of non-inferiority in patients with nAMD AMG 334 has a…
-
Press Release /Presentation of results from the Kisqali® (ribociclib) MONALEESA-7 Phase III trial exclusively studying premenopausal women with HR+/HER2- advanced breast cancer New MONALEESA-2 analyses…
-
Press Release /Sandoz strengthens position as global leader in biosimilars with new immunology data from four clinical studies for proposed biosimilars adalimumab and rituximab Efficacy and safety of biosimilar…
-
Press Release /Tasigna is the first and only second-generation tyrosine kinase inhibitor approved in the EU for the treatment of Ph+ CML-CP in children Approval builds on a series of Tasigna regulatory…
-
Press Release /Objective is to provide patients with rapid cancer diagnostics and appropriate care First focus will be on Ethiopia, Uganda and Tanzania Cancer is on the rise in Africa, with more than 500,000…
-
Press Release /Patients with episodic migraine taking erenumab reported significant and meaningful benefits over six months, with reduced migraine days and acute medication use Fifty percent of patients…
-
Press Release /New data showed switching moderate-to-severe, symptomatic COPD patients from Seretide®* to Ultibro® Breezhaler® improved lung function and was well tolerated. The FLASH…
-
Press Release /Kisqali plus an oral endocrine partner demonstrated significant efficacy with sustained benefit of nearly two years (median PFS 23.8 vs 13.0 months for endocrine therapy alone) and…